Group 1 - Lin Qingxuan Biotech Co., Ltd. submitted its prospectus to the Hong Kong Stock Exchange on May 29, aiming for a main board listing, potentially becoming the "first high-end domestic skincare stock" in Hong Kong [2] - Founded in 2003, the company specializes in anti-wrinkle and firming skincare products, featuring natural camellia flower ingredients, and has sold over 30 million bottles of its core product, camellia anti-wrinkle repair essence oil, since its launch in 2014 [2] - Financial data shows revenue growth from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with a compound annual growth rate of 32.3%, and net profit turning from a loss of 5.93 million yuan in 2022 to a profit of 187 million yuan in 2024 [2] Group 2 - The company operates 506 stores nationwide, with over 95% located in shopping malls, leading in store count among domestic and international high-end skincare brands [2] - Online sales are strong, with the company topping multiple essence oil sales rankings on Tmall in 2024, accumulating over 4.3 million active customers and an average annual repurchase rate of 34.6% [2] - The funds raised from the IPO will be primarily used for brand building, channel expansion, supply chain enhancement, technology research and development, brand matrix creation, and digitalization [3]

Core Viewpoint - The public dispute regarding the content of recombinant collagen in the product "Collagen Stick" from the brand Kefu Mei, owned by Giant Biological (02367.HK), has intensified, with accusations of misleading information about the actual collagen content [1][3]. Group 1: Company Response and Actions - Giant Biological received an apology from the testing agency used by the beauty blogger "Big Mouth Doctor" (Hao Yu) on May 30, and the company has sent products to multiple testing institutions for compliance checks [2][4]. - The company claims that multiple tests have shown collagen content greater than 0.1%, adhering to the standards set by the Chinese Pharmacopoeia [4]. - Giant Biological clarified that the rumors about the product "Collagen Stick 1.0" being taken off the shelves are false, stating it was a normal product iteration that began in April [6]. Group 2: Industry Context and Competitor Involvement - The controversy has drawn attention from competitors, notably Huaxi Biological, which publicly supported the claims made by "Big Mouth Doctor" and offered to assist in testing and regulatory communication [10]. - Huaxi Biological has criticized the overhyped claims surrounding recombinant collagen, suggesting that the industry is experiencing inflated expectations without sufficient scientific backing [13]. - The financial performance of Huaxi Biological has been declining, with a reported revenue of 5.371 billion in 2024, down 11.61% year-on-year, and a significant drop in net profit [13]. Group 3: Financial Performance of Giant Biological - Giant Biological has shown steady revenue growth from 1.19 billion in 2020 to 5.539 billion in 2024, with net profit increasing from 826 million to 2.062 billion during the same period [7]. - The Kefu Mei brand is a significant contributor to Giant Biological's revenue, accounting for 82% of total income in 2024, with a reported revenue of 4.542 billion [7]. - Concerns have been raised about the potential impact of the ongoing controversy on the company's performance during the critical 618 e-commerce promotion period [7].

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 手回集团 港股｜挂牌上市 据IPO早知道消息，手回集团有限公司（以下简称"手回集团"） 计划于2025年5月30日正式 以"2621"为股票代码在港交所主板挂牌上市。 手回集团在本次IPO发行中总计发行24,358,400股股份。其中，香港公开发售获990.00倍认购，国 际发售亦获1.13倍认购。此外，手回集团在本次IPO发行中引入天津海泰集团和鹿驰资本两位基石投 资者，累计认购约4955万港元。以每股8.08港元的发行价计算，手回集团本次IPO募资总额为1.97 亿港元。 成立于2015年的手回集团作为一家中国人身险中介服务提供商，致力于通过人身险交易与服务平 台，在线为投保人和被保险人提供保险服务解决方案。 目前，手回集团旗下拥有小雨伞、咔嚓保和牛保100三大平台，从而赋能于不同销售场景中的保险交 易及服务——在小雨伞进行在线直接分销；在咔嚓保通过保险代理人进行分销；在牛保100在业务合 作伙伴的协助下进行分销。 根据弗若斯特沙利文的资料，按2023 年的长期人身险的总保费计算，手回集团是中 ...

消费赴港上市潮。 作者 I 周佳丽 报道 I 投资界PEdaily 投资界-天天IPO获悉，上海林清轩生物科技股份有限公司已向港交所递交招股书，拟在主板挂牌上市，有望缔造港股"国货高端护肤第 一股"。 说起林清轩，其掌门人孙来春近年来在互联网上身影活跃。他在而立之年创办"林清轩"品牌，后来哥哥孙福春也加入一起创业。二十 年历程，林清轩除线上电商外，还在全国坐拥506家门店，旗下山茶花精华油累计卖出3000万瓶。同时身后站着SIG海纳亚洲、头头是 道、碧桂园创投、分享投资、凯辉基金、启承资本、雅戈尔等投资方。 此间正值港股价值重估的好时候，消费股更是火热。目睹蜜雪冰城、泡泡玛特、老铺黄金等逆袭，一批消费公司排队站在了港交所大 门前。 51岁东北大叔干护肤品 要去IPO了 你可能不知道，"林清轩"出自创始人年少时期的笔名。 出生于197 0年代，孙来春曾在学生时期办了一个文学社，作为领头人他给自己起了个笔名叫"林清轩"。后来从东北农业大学毕业后， 他就去牡丹江温春双鹤药业做管培生，从基层岗位干起，一干就是五年。 离开双鹤后，孙来春偶然遇到做外资护肤品代理的校友，和他参观品牌工厂时发现，护肤品行业与制药行业在底层逻 ...

林清轩业绩的快速增长很大程度得益于精华类明星单品的带动。光是精华油产品在2024年就贡献了4.48亿元的收 入，占总收入37%，在所有产品品类中占比最大，而这一比例前两年分别为31.5%和35.3%，呈现明显的上升趋 势。林清轩在招股书中提到：我们产品组合的核心是标志性的山茶花精华油，截至2024年12月31日，已累计销售 逾3000万瓶，根据灼识谘询的数据，按全渠道总零售额计自 2014年以来连续11年在所有面部精华油产品中稳居全 国榜首。该产品同时也在中国面部精华油品类中唯一连续8年零售额超过人民币1亿元的产品。 美妆赛道似乎在资本市场迎来回暖迹象。继毛戈平成功上市后，5月29日，上海林清轩生物科技股份有限公司（以 下简称"林清轩"）向港交所递交招股书，正式开启上市流程。凭借"山茶花精华油"这一明星单品切入国内高端护 肤赛道，林清轩在2024年实现营收12.1亿元，经调整后的净利润为2亿元，虽然营收和净利润并不算高，但毛利率 却高达82.5%。 林清轩近年加码布局线上渠道，业绩增长显著，但营销费用也连年上升，这几乎是所有头部国货美妆品牌的共性 问题。目前国内高端护肤市场大部分被国际大牌占领，作为国货美妆中 ...

众所周知，一款山茶花油连续十年蝉联中国面部精华油销售冠军，这一成绩背后，是国货美妆在高端市场 撕开的一道突破口。 近日，上海林清轩生物科技股份有限公司正式向港交所提交招股书。此次递交招股书的时间，恰逢国货美 妆集体进军高端市场的关键阶段。若成功上市，其将成为港股"国货高端护肤第一股"。 图源来自林清轩官方 这家以山茶花为核心原料的美妆企业，作为中国前15大高端护肤品牌中唯一的国货品牌，已开始与国际知 名品牌展开竞争。这也标志着中国护肤品市场正从"规模扩张"向"价值深耕"转变，国货品牌也在从"性价 比"竞争向"科技力"竞争升级。 国货高端化破局者，一瓶山茶花油的进击之路 天眼查显示，林清轩是上海本土原创品牌，自2003年创立以来，致力于以中国800米之上高山红山茶制作 出安全、天然、有效的化妆品。 林清轩的崛起是国货品牌在高端市场突围的教科书案例。作为中国高端国货护肤品牌的领导者，该品牌多 年聚焦抗皱紧致类护肤品行业，专注于提供天然、山茶花成分的高端护肤方案。 其核心产品林清轩山茶花抗皱修护精华油已连续11年稳居全国面部精华油榜首。从1.0到4.0版本，这个被 粉丝称为"小皇瓶"的明星单品累计产销突破2000万 ...

Group 1 - The 2025 Shanghai Cooperation Organization (SCO) Media Cooperation Forum was held in Urumqi, Xinjiang, with over 300 representatives from 26 countries discussing cooperation under the theme "Building a Better Home Together for a Prosperous Future" [1] - Since its establishment in 2001, the SCO has adhered to the "Shanghai Spirit" of mutual trust, mutual benefit, equality, consultation, respect for diverse civilizations, and seeking common development [1] - China will assume the rotating presidency of the SCO for 2024-2025, with expectations for China to lead new cooperation initiatives and strengthen the collective power of developing countries in global governance [1] Group 2 - The domestic skincare brand Gu Yu showcased its product "Four Seasons Boundless," which combines Chinese efficacy skincare technology with poetic aesthetics, attracting attention from international guests [3] - Gu Yu focuses on Chinese skin types and ingredients, exploring a path of scientific skincare centered on Chinese characteristics, reflecting the cultural depth and research strength of Chinese cosmetic brands [3][4] - The "Four Seasons Boundless" includes two products, "Boundless Electric Cream" and "Four Seasons Spiritual Dew," showcasing Gu Yu's research and innovation capabilities [4] Group 3 - "Boundless Electric Cream" utilizes three core technologies, including self-developed composite enzyme biomimetic transformation technology, plant stem cell culture technology, and synthetic biology technology, featuring key active ingredients like rare ginseng saponin CK and snow lotus stem cells [4] - "Four Seasons Spiritual Dew" is formulated with seasonal herbs such as ginseng and peony, aiming to provide revitalizing energy for consumers seeking a healthy complexion [4] - Gu Yu has established a library of "Chinese core" active ingredients, including aurora licorice and rare ginseng saponin CK, to meet diverse skincare needs across different consumer segments [4] Group 4 - Gu Yu has maintained its commitment to promoting Chinese culture through skincare products, with the "Four Seasons Boundless" adopting a unique design inspired by traditional Chinese aesthetics, winning multiple international design awards [6] - The brand aims to showcase its determination to empower "Chinese core" ingredients and efficacy to the world, while expressing cultural confidence and charm through its products [8]

Group 1 - The core viewpoint of the article highlights the dual nature of celebrity endorsements in brand marketing, where they can drive sales but also pose significant risks to brand reputation [1] - The brand endorsement market is expected to grow in 2024, with 1,222 brands announcing endorsements, an 11% increase from the previous year [2] - Top-tier celebrities are commanding endorsement fees exceeding 10 million yuan, equivalent to the annual net profit of many small to medium-sized enterprises [2] Group 2 - The case of the brand Perlayah, which saw a significant increase in exposure and interaction after announcing a partnership with celebrity Yi Yang Qianxi, illustrates the potential for immediate sales impact through celebrity endorsements [2][4] - The gum category has shown a remarkable sales growth rate of 38.89% in 2024, indicating a strong market performance [5] - The top three brands in the gum market, Stride, Green Arrow, and Yida, have increased their market share from 88% in 2023 to 92% in 2024, with each brand's growth rate exceeding 20% [6] Group 3 - The endorsement of the youth group "Times Youth" by Stride led to a 23.6% increase in sales after the announcement, demonstrating the strong influence of celebrity endorsements on consumer purchasing decisions [8] - Stride's market share surged by 8.7 percentage points in April, significantly outperforming a competing brand that saw a decline [10] - The social media engagement from the youth demographic contributed 72% of Stride's brand voice, indicating a successful alignment with the target audience [12] Group 4 - The article discusses the trend of brands utilizing non-human endorsements, such as animals and self-created IPs, to mitigate risks associated with celebrity endorsements [15][30] - The use of virtual digital personas for brand endorsements is on the rise, with examples of successful collaborations with beauty brands [40] - Brands are increasingly adopting multi-dimensional endorsement strategies to diversify risk and maximize brand communication effectiveness [51]

成立于 2003年的林清轩作为一个 中国高端国货护肤品牌，聚焦抗皱 紧致 类护肤品市场 。其中， 旗舰品牌 「 林清轩 」专注 提供基于天然、山茶花成分的高端护肤改善方案 。 2024年中国前15大高端护肤品牌中唯一的国货品牌。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据 IPO早知道消息， 上海林清轩生物科技股份有限公司 （以下简称 " 林清轩 "）于2025年5月29 日正式向港交所递交招股说明书，拟主板挂牌上市，中信证券和华泰国际担任联席保荐人。 2012年 ，林清轩 展开山茶花护肤品研究 ，后于 2014年推出核心大单品 「 山茶花精华油 」，这 一产品为林清轩 的核心以油养肤产品线奠定 了 基础 ， 山茶花精华油现为第五代升级版 。 截至 2024 年12月31日，自其推出以来的累计销量突破3,000 万瓶，且根据灼识 咨询 的资料，按全渠 道总零售额计自 2014年以来连续11年 在 所有面部精华油产品中稳居全国榜首 ， 亦为中国面部精 华油品类中连续 8年零售额超过1亿元 人民币 的唯一一款产品 。 除这一大单品外，林清轩 持续研发核心成分和打造多 ...

Core Viewpoint - Lin Qingxuan is poised to become the first high-end domestic skincare stock in Hong Kong, having submitted its prospectus to the Hong Kong Stock Exchange, highlighting its leadership in the high-end domestic skincare market in China [1] Industry Overview - The Chinese cosmetics market is expanding, driven by increased consumer focus on health and appearance, digital transformation in shopping behavior, and innovation in cosmetics [1] - The skincare segment holds the largest market share, with the market size growing from RMB 332.9 billion in 2019 to RMB 461.9 billion in 2024, reflecting a compound annual growth rate (CAGR) of 6.8% [1] Company Performance - Lin Qingxuan's total revenue is projected to grow from RMB 691 million in 2022 to RMB 1.21 billion in 2024, achieving a CAGR of 32.3% [2] - The company's net profit is expected to reach RMB 187 million in 2024 [2] Market Trends - The market for high-end anti-wrinkle and firming skincare products is anticipated to increase from RMB 59.4 billion in 2024 to RMB 155.5 billion by 2029, with a CAGR of 21.2% [2] - The overall high-end skincare market in China is expected to reach RMB 218.5 billion by 2029, with a CAGR of 13.8% from 2024 to 2029 [2] Strategic Outlook - As a leading brand in the high-end domestic skincare sector, Lin Qingxuan is expected to benefit from its strong R&D capabilities and existing product leadership [2] - The company aims to align its product strategy with evolving consumer demands, focusing on core products and expanding its product matrix to offer customized skincare solutions [2]